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Editorial Comment 
Aminophylline for Angina: 
The “Robin Hood” Effect?* 
RICHARD 0. CANNON III, MD, FACC 
Bethesda, Maryland 
In normally perfused myocardium, coronary blood flow is 
greater within the endocardium than in the epicardium 
because of greater metabolic activity and oxygen require- 
ments. Adequate perfusion is maintained by local autoregu- 
lation with greater vasodilation of endocardial arterioles 
compared with the more constricted epicardial arteriolar bed 
(l), with alpha-adrenergic tone probably contributing to 
maintaining an arteriolar resistance gradient from epicar- 
dium to endocardium (2). In coronary artery disease, de- 
creased perfusion pressure distal to an obstructive athero- 
sclerotic plaque in epicardial coronary arteries necessitates 
even greater endocardial arteriolar vasodilation to maintain 
appropriate endocardial oxygen delivery at the cost of 
further compromising vasodilator capacity. Any interven- 
tion that increases myocardial oxygen consumption further 
dilates the arterioles; the resulting increase in flow creates 
increased viscous and turbulent energy losses across the 
obstruction, which lead to a further drop in distal coronary 
perfusion pressure. This pressure drop compromises perfu- 
sion of the maximally vasodilated endocardium because of a 
redistribution of blood from endocardium to epicardium 
(transmural “steal”) (3-7). Mediators for arteriolar vasodi- 
lation probably include adenosine, withdrawal of alpha- 
adrenergic tone, tissue hypoxia, increased local partial pres- 
sure of carbon dioxide (Pco,) and tissue acidosis among 
other possibilities and may differ for ischemic as opposed to 
nonischemic myocardium (1). 
Aminophylline and coronary artery flow. For many years, 
adenosine has been known to be a potent coronary arteriolar 
vasodilator (8), similar in potency to reactive hyperemia 
after brief coronary occlusion. More recently, antagonism of 
adenosine-mediated coronary vasodilation by aminophylline 
has been demonstrated (9). Thus, at first glance, aminophyl- 
line would seem to be an unlikely choice as a useful drug in 
coronary artery disease, where the coronary flow response 
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to stress is already limited. Further, methylxanthines in- 
crease myocardial contractility and myocardial oxygen de- 
mands. Initial interest in aminophylline for use in coronary 
artery disease was promoted by interest in its cyclic nucle- 
otide phosphodiesterase inhibitor activity, resulting in in- 
creased cyclic adenosine monophosphate with smooth mus- 
cle relaxation. In coronary vascular tissue, this would 
presumably produce vasodilation. However, in intact con- 
scious dogs, aminophylline actually causes an increase in 
coronary and systemic vascular resistance when infused 
systemically, a response prevented by alpha-adrenergic 
blockade (10). Therefore, in contrast to the direct relaxant 
effect of aminophylline on smooth muscle, the net systemic 
effect of aminophylline on coronary and systemic vascular 
tissue is vasoconstriction contributed to by activation or 
enhancement of alpha-adrenergic receptors, and blockade of 
adenosine receptors, which mediate vasodilation. The vaso- 
constrictor impact of aminophylline might be greater in the 
epicardium, already under tonic alpha-adrenergic influence, 
in contrast to the endocardium, where vessels are subjected 
to more autoregulatory vasodilating mediators and less alpha 
adrenergic tone. Both of these attenuate aminophylline’s 
vasoconstrictor effects. 
The “Robin Hood” effect in coronary artery disease. 
Earlier this year, Picano et al. (11) and Crea et al. (12) 
independently reported benefit of intravenously adminis- 
tered aminophylline (or theophylline) during exercise of 
patients with coronary artery disease in blinded, random- 
ized, placebo-controlled studies. Although prolongation in 
time to onset of angina during exercise (or prevention of 
angina) might have been due in part to aminophylline’s 
blockade of adenosine-stimulated pain receptors (13), pro- 
longation of the time to ST segment depression and an 
increase in rate-pressure product at the time of ST segment 
depression, in addition to significant prolongation in the 
duration of exercise, suggests a true anti-ischemic effect of 
aminophylline. Both groups postulated that aminophylline 
prevented the transmural redistribution of coronary flow 
from endocardium to epicardium by inhibiting epicardial 
arteriolar vasodilation during stress. The British group 
dubbed this the “Robin Hood” effect (12) with blood di- 
verted from the oxygen-“rich” epicardium to the oxygen- 
“poor” endocardium. 
The present study: aminophylline in syndrome X. In this 
issue of the Journal, Emdin and co-workers demonstrate 
remarkable improvement in effort duration, rate-pressure 
product achieved, and symptom response during bicycle 
exercise with abolition of ischemic-appearing ST segment 
responses after aminophylline infusion in eight women with 
syndrome X (defined as angina1 chest pain, angiographically 
normal coronary arteries and ischemic-appearing ST seg- 
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ment responses to exercise and dipyridamole infusion). 
There is mounting evidence that a subset of patients with 
angina1 chest pain, despite angiographically normal coronary 
arteries, have functionally abnormal coronary arteries (es- 
pecially small intramural coronary arteries, prompting us to 
call this syndrome “microvascular angina”) with reduction 
of vasodilative responses to pharmacologic stimuli (dipyrida- 
mole, contrast dye, calcium channel blockers) and stress 
(rapid atria1 pacing, exercise) and a heightened vasoconstric- 
tor sensitivity to ergonovine and cold pressor testing (U-24). 
Emdin, et al. (14) argue that aminophylline’s benefit 
might be due to prevention of transmural redistribution of 
coronary flow away from endocardium during stress. The 
hydrodynamic principle supporting this hypothesis, de- 
scribed previously for epicardial coronary disease, might 
hold true in syndrome X if the obstruction to coronary flow 
were moved further “downstream” because of inappropri- 
ately constricted small coronary arteries (25). This hypoth- 
esis is speculative in this study because no measure of 
coronary flow reserve (to stress or pharmacologic vasodila- 
tor) was performed before or after aminophylline. Further, 
methodology is not yet available to accurately quantitate 
endocardial versus epicardial myocardial perfusion in hu- 
mans to investigate aminophylline’s effect on perfusion 
distribution in patients with syndrome X or coronary artery 
disease. 
Implications. With more demonstrations of exercise and 
symptom benefit in larger numbers of patients (including 
men) and with oral preparations of aminophylline or the- 
ophylline that do not cause unacceptable side effects or 
toxicity, there may be a major therapeutic option for patients 
with syndrome X (and coronary artery disease), many of 
whom continue to experience frequent chest pain despite use 
of conventional antianginal medications. 
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